small molecule

REVTORPYK

GEDATOLISIB

Loss of exclusivityJuly 2031FDA regulatory exclusivity expiry

CompanyCELCUITY INC

Drug detail

Brand name	REVTORPYK
Active ingredient	GEDATOLISIB
Strength	180MG/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	July 2026
Marketing status	RX

Regulatory exclusivity

Code	Expires
NCE	July 2031

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.